\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[T2A]{fontenc}
\usepackage[ngerman,polish,english]{babel}



\usepackage{float}








\begin{document}

\title{Comparison of the Effect of Hydroxychloroquine Versus Favipiravir on
SARS-CoV-2 PCR Conversion Time in Healthcare Workers with COVID-19}



\author[1]{Mustafa Çörtük}%
\author[2]{Unal Güvenç}%
\author[3]{Pakize Sucu}%
\author[3]{Ercan Çeğilli}%
\author[4]{Şeyma Başlılar}%
\author[5]{Kürşad Nuri Baydili}%
\author[1]{Melih Akay Arslan}%
\author[6]{Mualla Kök}%
\author[1]{Halit Çınarka}%
\affil[1]{Faculty of Medicine, University of Health Sciences, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital}%
\affil[2]{Kanuni Sultan Süleyman Research and Training Hospital}%
\affil[3]{Arnavutköy Public Hospital}%
\affil[4]{Faculty of Medicine, University of Health Sciences, Umraniye Training and Research Hospital}%
\affil[5]{, Institute of Graduate Studies, Istanbul University Cerrahpaşa}%
\affil[6]{Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital}%


\vspace{-1em}



  
  \date{June 05, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
Background and aim: Coronavirus disease 2019 (COVID-19) has spread
rapidly all over the world and has become a pandemic. Although negative
reports have been reported about the use of hydroxychloroquine (HCQ) in
patients with moderate to severe disease and hospitalized COVID-19
patients, its effect on RT-PCR negativity is unknown, mostly in mild
disease and outpatients. In this study, the effects of HCQ and
favipiravir on RT-PCR negation were compared. Methods: In this
multicenter, retrospective, cross-sectional study, consecutively
presenting COVID-19 patients who were positive for RT-PCR between 13
March 2020 and 15 January 2021 were analyzed. Negative RT-PCR results
and times were recorded in the follow-up of the patients. All of the
patients included in the study consisted of heathcareworkers and the
patients were divided into two groups as HCQ or favipiravir users.
Results: The favipiravir and HCQ patient groups were similar in terms of
age, gender, comorbidities, and hospitalization rate. The median number
of PCR-negative cases on the seventh day of treatment was significantly
higher in the HCQ group (p = 0.007). The median RT-PCR negation time was
9 days in the HCQ group versus 10 days in the favipiravir group (p =
0.006). Conclusion: The use of HCQ shortens the RT-PCR negative time
compared to favipiravir in patients who are in the relatively young age
group and have a definite diagnosis of COVID-19. This result is
important in terms of viral spread and contamination. There were no side
effects that required a change in treatment in either drug group.%
\end{abstract}%



\sloppy


\textbf{Hosted file}

\verb`Main_Manuscript_2.docx`  available at \url{https://authorea.com/users/733079/articles/711013-comparison-of-the-effect-of-hydroxychloroquine-versus-favipiravir-on-sars-cov-2-pcr-conversion-time-in-healthcare-workers-with-covid-19}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/300Dpi/300Dpi}

\end{center}
\end{figure}

\textbf{Hosted file}

\verb`Tables.docx`  available at \url{https://authorea.com/users/733079/articles/711013-comparison-of-the-effect-of-hydroxychloroquine-versus-favipiravir-on-sars-cov-2-pcr-conversion-time-in-healthcare-workers-with-covid-19}

\selectlanguage{english}
\FloatBarrier
\end{document}

